Could a wakefulness drug beat fatigue in IBD patients?
NCT ID NCT07582458
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether modafinil, a drug used for sleep disorders, can reduce severe fatigue in adults with inactive inflammatory bowel disease (IBD). Sixty participants will take either modafinil or a placebo for 8 weeks, starting at 100 mg daily with possible dose increases. The main goal is to see if fatigue scores improve more with modafinil than with placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Modafinil
What this could lead to
If it works, this could offer a new treatment option for severe fatigue in people with inactive inflammatory bowel disease.
What could go wrong
This is a small, early-phase trial (Phase 2/3) with only 60 participants. The drug may not prove more effective than placebo, and side effects like headache or anxiety are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••